Pfizer Inc. (NYSE:PFE) Holdings Decreased by Sfmg LLC

Sfmg LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,090 shares of the biopharmaceutical company’s stock after selling 2,018 shares during the quarter. Sfmg LLC’s holdings in Pfizer were worth $319,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Front Street Capital Management Inc. raised its position in Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 215 shares in the last quarter. Castleview Partners LLC increased its stake in Pfizer by 2.4% in the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 287 shares in the last quarter. United Bank increased its stake in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. Compton Capital Management Inc. RI increased its stake in Pfizer by 0.5% in the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock worth $3,308,000 after purchasing an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. increased its stake in Pfizer by 2.4% in the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 307 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PFE shares. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

PFE opened at $25.41 on Thursday. The stock has a market cap of $143.86 billion, a PE ratio of 70.57, a P/E/G ratio of 1.16 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1 year low of $25.26 and a 1 year high of $41.33. The stock’s 50 day simple moving average is $27.19 and its 200-day simple moving average is $28.76.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.14 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.